Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer

CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer

Thumbnail Image
Download
Name

513.full.pdf

Description
Published version
Size

1.84 MB

Format

Adobe PDF

Checksum (MD5)

4eb656b2d10a210125aea53039e550a2

sword-2020-03-30T13:24:06.original.xml (130 B)
Original SWORD entry document
Author(s)
Ng, Sheng Rong
•
Rideout, William M.
•
Akama-Garren, Elliot H.
•
Bhutkar, Arjun
•
Mercer, Kim L.
•
Schenkel, Jason M.
•
Bronson, Roderick T.
•
Jacks, Tyler E
Date Issued
December 2019
Journal
Proceedings of the National Academy of Sciences of the United States of America
Publisher
Proceedings of the National Academy of Sciences
Citation
Ng, Sheng Rong et al. "CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer." Proceedings of the National Academy of Sciences of the United States of America 117, 1 (January 2020): 513-521 ©2020 National Academy of Sciences.
Version
Final published version
Abstract
Small cell lung cancer (SCLC) is a highly aggressive subtype of lung cancer that remains among the most lethal of solid tumor malignancies. Recent genomic sequencing studies have identified many recurrently mutated genes in human SCLC tumors. However, the functional roles of most of these genes remain to be validated. Here, we have adapted the CRISPR-Cas9 system to a well-established murine model of SCLC to rapidly model loss-of-function mutations in candidate genes identified from SCLC sequencing studies. We show that loss of the gene p107 significantly accelerates tumor progression. Notably, compared with loss of the closely related gene p130, loss of p107 results in fewer but larger tumors as well as earlier metastatic spread. In addition, we observe differences in proliferation and apoptosis as well as altered distribution of initiated tumors in the lung, resulting from loss of p107 or p130. Collectively, these data demonstrate the feasibility of using the CRISPR-Cas9 system to model loss of candidate tumor suppressor genes in SCLC, and we anticipate that this approach will facilitate efforts to investigate mechanisms driving tumor progression in this deadly disease. Keywords: small cell lung cancer; CRISPR; GEMM
Subjects
Multidisciplinary
MIT Department
Massachusetts Institute of Technology. Department of Biology
Harvard University--MIT Division of Health Sciences and Technology
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
https://hdl.handle.net/1721.1/125148
DOI of Published Version
https://doi.org/10.1073/pnas.1821893117
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.